Last reviewed · How we verify

ASA-withdrawn group — Competitive Intelligence Brief

ASA-withdrawn group (ASA-withdrawn group) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

phase 3 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ASA-withdrawn group (ASA-withdrawn group) — Hospital Universitari Vall d'Hebron Research Institute. ASA-withdrawn group refers to a cohort of patients who discontinued aspirin therapy, typically studied to assess rebound thrombotic or cardiovascular effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ASA-withdrawn group TARGET ASA-withdrawn group Hospital Universitari Vall d'Hebron Research Institute phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASA-withdrawn group — Competitive Intelligence Brief. https://druglandscape.com/ci/asa-withdrawn-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing